[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tianjin Medical University Eye Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":144},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,67,95,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100648987","early-phase-1-biomarkers-effectiveness-and-safety-of-aflibercept-8mg-modified-fixed-dose-regimen-in-treatment-nave-namd-patients-100648987",false,"NCT07728981","Biomarkers, Effectiveness, and Safety of Aflibercept 8mg Modified Fixed Dose Regimen in Treatment-Naïve nAMD Patients","A Prospective, Multicenter, Open-Label Phase IV Clinical Study to Evaluate the Biomarkers, Effectiveness, and Safety Based On A Modified Fixed Dose Regimen of Aflibercept 8mg in Treatment-Naïve Patients With Neovascular Age-Related Macular Degeneration (nAMD)","Inclusion Criteria:\n\n1. Patients who fully understand the content, procedures, and possible adverse events (AEs) of this study and are able to provide written informed consent;\n2. Male or female patients aged ≥50 years at the time of signing the informed consent;\n3. Women of childbearing potential (WOCBP) must agree to use dual contraception during the study and for 4 months after discontinuation of study treatment, consisting of one medically recognized contraceptive method with a failure rate of less than 1% per year (see Appendix 1 for Contraceptive Measures, Definitions and Requirements for Women of Childbearing Potential) combined with a barrier method (e.g., condom). Women who have undergone surgical sterilization (such as hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or menopause for more than 1 year are considered not of childbearing potential. Women of childbearing potential must have a negative pregnancy test at screening and must not become pregnant, breastfeed, lactate, or plan pregnancy, breastfeeding, or egg donation during the study and for 4 months after discontinuation of study treatment;\n4. Male subjects whose partners are of childbearing potential must agree to use dual contraception during the study and for 4 months after the end of treatment, consisting of one medically recognized contraceptive method with a failure rate of less than 1% per year (see Appendix 1 for Contraceptive Measures, Definitions and Requirements for Women of Childbearing Potential) combined with a barrier method (e.g., condom), and must agree not to donate sperm during the study and for 4 months after the end of treatment.\n\n   Inclusion Criteria for Study Eye\n\n   Subjects included in this study must meet all of the following ocular inclusion criteria for the study eye:\n5. Have sufficiently clear ocular media and adequately dilated pupils to obtain high-quality retinal images for diagnosis;\n6. Untreated nAMD with active subfoveal choroidal neovascularization (CNV), with total CNV area accounting for more than 50% of the total lesion area.\n7. SD-OCT examination showed the presence of intraretinal fluid (IRF) and\u002For subretinal fluid (SRF) in the foveal center of the retina.\n8. During the screening and baseline periods, BCVA scores measured using the ETDRS visual acuity chart at an initial testing distance of 4 meters ranged from 78 to 24 ETDRS letters (inclusive) (approximately equivalent to Snellen visual acuity 20\u002F32 to 20\u002F320), and the vision loss was caused by nAMD.\n\nExclusion Criteria:\n\n1. Patients who have received other investigational treatments (including anti-VEGF, corticosteroids, laser photocoagulation treatments \\[panretinal photocoagulation or macular photocoagulation\\], and photodynamic therapy \\[PDT\\]) or approved nAMD drugs\u002Ftherapies;\n2. Patients with allergies or hypersensitivity reactions to any component\u002Fexcipient of the investigational product;\n3. Uncontrolled hypertension (defined as systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>95 mmHg). Subjects may be treated with up to three known antihypertensive drugs to achieve adequate blood pressure control. This restriction applies to drugs that can be used for treating hypertension, even if the primary purpose of taking the drug for the subject is not blood pressure control. Any medication known to affect blood pressure must have a stable regimen for 12 weeks prior to screening;\n4. History of other diseases, metabolic dysfunctions, abnormal physical examinations, or clinical laboratory abnormalities that reasonably suggest a contraindication to the investigational drug, may interfere with the interpretation of study results, or could place the patient at high risk for treatment-related complications;\n5. Any condition that, in the opinion of the investigator, may affect the patient's ability to provide informed consent, comply with the study protocol, complete the study according to study procedures, or for which the patient's participation may affect the study results or their own safety; Exclusion criteria for study eye\n6. Any eye with diabetic retinopathy (DR), diabetic macular edema (DME), or any retinal vascular disease other than nAMD;\n7. Presence of extraocular\u002Fperiocular infection or inflammation in any eye during the screening or baseline period;\n8. Presence of retinal pigment epithelium (RPE) tear or rupture, scarring, fibrosis, or atrophy involving the fovea;\n9. Fluorescein angiography (FA)\u002Ffundus photography (FP) showing:\n\n   1. Total lesion area (including hemorrhage, scarring, and neovascularization) greater than 12 disc areas (30.5 mm²);\n   2. Fibrosis or atrophy \\>50% of the total lesion area, and\u002For involving the fovea.\n10. Any intraocular disease that the investigator believes may reduce vision improvement or require medical or surgical intervention during the study (such as amblyopia, aphakia, retinal detachment, cataract, diabetic retinopathy or maculopathy, epiretinal membrane with traction):\n\n    1. Presence of vitreous hemorrhage during the screening or baseline period;\n    2. Uncontrolled glaucoma (intraocular pressure still \\>25 mmHg despite anti-glaucoma medication);\n    3. Any cataract surgery or treatment for cataract surgery complications with steroids or yttrium-aluminum garnet (YAG) laser capsulotomy within 3 months prior to Day 1 of the study;\n    4. Any prior intraocular surgery (e.g., vitrectomy, glaucoma surgery, corneal transplantation, or radiation therapy);\n    5. Prior periocular or intravitreal drug injections (including anti-VEGF agents) for other retinal diseases;\n    6. Presence of intraocular inflammation\u002Finfection in any eye within 12 weeks prior to the screening visit;\n    7. History of idiopathic or autoimmune-related uveitis in the study eye.","ALL","50 Years","85 Years",{"count":20,"type":21},49,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","Primary objective:\n\n• To evaluate the change in aqueous humor vascular endothelial growth factor A (VEGF-A) levels after 2 months of initial treatment with 8 mg Aflibercept in treatment-naïve nAMD patients.\n\nSecondary objectives:\n\n• To assess the efficacy, safety, and biomarker changes of 8 mg Aflibercept using a modified fixed-interval dosing regimen over 12 months in treatment-naïve nAMD patients.",[27],"Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD",[29,30,31],"Neovascular Age-Related Macular Degeneration","Aflibercept 8mg","Modified Fixed Dose Regimen","NOT_YET_RECRUITING","2026-07-22",{"date":35,"type":36},"2026-07-27","ACTUAL",{"date":38,"type":21},"2026-07-25",{"date":40,"type":21},"2027-12-31",{"name":42,"class":43},"Tianjin Medical University Eye Hospital","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100646322","impact-of-various-myopia-management-strategies-on-asthenopia-among-pediatric-and-adolescent-populations-100646322","NCT07691671","Impact of Various Myopia Management Strategies on Asthenopia Among Pediatric and Adolescent Populations","Inclusion Criteria:\n\n* ① Children and adolescents with myopia attending the Optometry Centre of Tianjin Medical University Eye Hospital;\n\n  * Age range 6-18 years, grouped by chronological age at 12 and 13 years into a children's group (6-12 years) and an adolescent group (13-18 years), irrespective of sex; ③ Current use of one or a combination of the following interventions: a. conventional single-vision spectacle lenses; b. defocus-inducing spectacles (multifocal or peripheral defocus design); c. orthokeratology (OK) lenses; d. low-concentration atropine eye drops (0.01%); e. red-light therapy; f. no myopia control intervention; ④ Best-corrected visual acuity (BCVA) ≥ 0.8 on the standard logarithmic visual acuity chart; ⑤ Written informed consent obtained from guardians, and assent obtained from children aged 8 years and older.\n\nExclusion Criteria:\n\n* ① Individuals residing in plateau or high-wind areas;\n\n  * Individuals with a history of any ophthalmic surgery;\n\n    * Individuals diagnosed with psychiatric disorders such as anxiety disorder, depressive disorder, bipolar disorder, or somatic symptom disorder by a psychiatrist, or those who have taken psychoactive medications (e.g., anxiolytics, antidepressants, sedative-hypnotics) within the past 3 months; ④ Individuals with ocular diseases or conditions including keratoconus, strabismus, conjunctivitis, amblyopia, high myopia, glaucoma, cataract, retinal nerve defects, or systemic diseases such as diabetes, hypertension, arthritis, osteoporosis, thyroid disease, chronic migraine, or chronic headache, or those taking medications known to potentially induce asthenopia; ⑤ Others: inability to cooperate with subjective questionnaire completion or objective examinations; or other conditions deemed unsuitable for inclusion by the investigators.","6 Years","18 Years",{"count":53,"type":21},600,"OBSERVATIONAL","Different myopia control interventions have certain effects on ocular asthenopia in children and adolescents. As children and adolescents are in a critical period of visual development, the presence of asthenopia may lead to an earlier onset and increased prevalence of a range of chronic eye diseases and retinal disorders, thereby affecting their physical and mental health as well as future development. However, existing studies have mostly focused on single interventions, lacking a systematic comparison of the effects of multiple myopia control approaches on asthenopia. Therefore, the present study aims to investigate, through a cross-sectional survey, the impact of various myopia control interventions-including conventional spectacles, defocus-inducing spectacles, orthokeratology, low-concentration atropine, red-light therapy, and combined multi-intervention strategies-on asthenopia, to assess the prevalence and severity of asthenopia among users of different interventions, and to compare the differences in their effects on asthenopia. This will provide evidence-based support for the selection of individualised correction strategies in clinical practice and contribute to advancing clinical research on asthenopia in children and adolescents.",[57,58],"Myopia","Visual Fatigue","2026-07-02",{"date":61,"type":36},"2026-07-09",{"date":63,"type":21},"2026-07-05",{"date":65,"type":21},"2027-04-30",{"name":42,"class":43},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100630986","efficacy-of-different-interventions-for-progressive-myopia-after-orthokeratology-lens-wear-100630986","NCT07494799","Efficacy of Different Interventions for Progressive Myopia After Orthokeratology Lens Wear","A Prospective Study on the Efficacy of Different Interventions for Progressive Myopia in Children After Orthokeratology Lens Wear","Inclusion Criteria:\n\n1\\) The initial fitting age is between 8-12 years, irrespective of gender; 2) The spherical equivalent refraction (SE) of both eyes at the initial fitting falls within the manufacturer's approved range of -6.00D to -0.50D; 3) The best corrected visual acuity of both eyes is ≥1.0 (Snellen); 4) The ability to ensure overnight Ortho-K lens wear for a duration of 8 to 10 hours; 5) No prior history of ocular trauma or surgery; 6) No prior history of acute or chronic ocular inflammation, such as keratoconjunctivitis or abnormal tear film; 7) The ability to meticulously adhere to instructions for lens care and attend regular follow-up examinations; 8) The standard use of other myopia progression interventions, such as 0.01% atropine or red-light therapy as prescribed; 9) Comprehensive follow-up data; 10) At least one eye exhibits an annual axial length elongation of \\>0.30 mm during the first year of Ortho-K lens wear.\n\nExclusion Criteria:\n\n1\\) Axial length elongation less than 0.30 mm in both eyes during the first year of Ortho-K treatment; 2) Incidence of significant complications during the study period, such as recurrent corneal inflammation; 3) Incomplete data or cases lost to follow-up; 4) SE of either eye less than -6.00D, or astigmatism greater than -2.00D; 5) Unstable vision during Ortho-K treatment, characterized by multiple instances of vision below 0.2 (LogMAR); 6) Change in the brand of Ortho-K lens.\n\nThis study utilized a retrospective data collection approach. To prevent the influence of non-independent data from both eyes of a single participant on statistical analyses, data from only one eye per subject were included in the final analysis. The selection criterion prioritized data from the right eye; however, if the right eye did not satisfy the primary inclusion criterion of \"annual axial elongation \\>0.30 mm,\" data from the left eye were used instead. This study was conducted in accordance with the Declaration of Helsinki and received approval from the Ethics Committee of the Tianjin Medical University Eye Hospital. Informed consent was obtained from the guardians of all participating children.","8 Years","12 Years",{"count":77,"type":21},3890,"Myopia has emerged as a significant concern impacting the visual health of children and adolescents on a global scale. According to research conducted by Holden BA et al., it is projected that by the year 2050, the worldwide prevalence of myopia and high myopia will experience a substantial increase, affecting approximately 5 billion and 1 billion individuals, respectively, with particularly high prevalence rates observed in East Asia\\[1\\]. The persistent rise in myopia incidence, coupled with the escalation of complications associated with high myopia, is anticipated to exert complex socio-economic repercussions \\[2\\]. Consequently, the prevention of myopia onset and the management of axial length elongation have become critically important \\[3\\].\n\nOrthokeratology (Ortho-K) is a procedure that involves the overnight application of specially designed reverse geometry rigid gas permeable contact lenses to achieve temporary corneal reshaping and reduce myopia during the day\\[4,5\\]. In children with mild to moderate myopia, Ortho-K has demonstrated visual correction efficacy ranging from 80% to 92%\\[6,7\\]. Nonetheless, its efficacy in controlling myopia progression may not match its corrective efficacy. The therapeutic effect of Ortho-K in decelerating axial elongation is reported to range from 43% to 63%. Despite the use of Ortho-K, approximately 15% of children continue to exhibit rapid axial elongation exceeding 0.36 mm per year.\\[8,9\\].\n\nIn recent years, adjunctive interventions such as low-concentration atropine eye drops, modification of the back optical zone diameter (BOZD) of orthokeratology (Ortho-K) lenses, and low-level red-light therapy (RLRL) have been proposed to augment the myopia control efficacy of Ortho-K. Zhao et al. \\[10\\] reported that after one year of treatment with either atropine orthokeratology (AOK) or Ortho-K lenses in children aged 5-14 years, the axial length (AL) increased by 0.14 mm and 0.29 mm, respectively. Another study involving children aged 8-12 years \\[11\\] demonstrated that after one year of treatment, the AOK group exhibited a 17% reduction in AL growth (0.20 mm vs. 0.24 mm). Research conducted by Xiong et al. \\[12\\] indicated that for children whose eyes elongated by at least 0.50 mm within one year of Ortho-K wear, the combination of RLRL therapy with Ortho-K significantly reduced axial elongation compared to Ortho-K alone. Additional studies have suggested that decreasing the BOZD can enhance the extent and degree of mid-peripheral corneal steepening, thereby decelerating axial elongation \\[13-15\\].\n\nMost existing studies primarily compare a single intervention against a control group, thereby lacking direct \"head-to-head\" comparisons. Traditional meta-analyses are limited to comparing two interventions at a time and often fail to assess multiple treatments concurrently. Consequently, most meta-analyses offer only statistical insights into the efficacy of individual interventions. Clinically, it is common to combine two or more interventions to treat myopia, particularly in cases of rapidly progressive myopia. Previous research has indicated that combined interventions may have additive effects in the prevention and control of myopia; however, these findings require further empirical validation.\n\nThis study employs a retrospective approach to evaluate the efficacy of various treatment strategies in managing axial elongation in children aged 8-12 years who experience rapid axial progression following Ortho-K lens wear. The objective is to provide a scientific foundation for the development of personalized myopia control plans.",[80,81,82],"Progressive Myopia","Pediatric Myopia","Orthokeratology-related Myopia Progression",[84,85,86,87],"Repeated low-level red-light therapy","Orthokeratology","Atropine","Small optical zone design","2026-03-26",{"date":90,"type":36},"2026-04-01",{"date":90,"type":21},{"date":93,"type":21},"2027-04-01",{"name":42,"class":43},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":16,"minAge":50,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":4},"100627485","phase-1-protect-study-prospective-research-on-optimizing-atropine-concentration-escalation-for-childrens-myopia-prevention-100627485","NCT07449247","PROTECT-Study: Prospective Research on Optimizing Atropine Concentration Escalation for Children's Myopia Prevention","PROTECT","Inclusion criteria:\n\n1. A written informed consent form signed by the child and their legal guardian has been obtained.\n2. Children aged 6 to 9 years (inclusive).\n3. Equivalent spherical diopter of computerized refraction after bilateral ciliary muscle paralysis: 0D\\\u003CSE. The upper limit standards for SE are set as follows for different age groups: 6 years old: P25 = +1.13D,7 years old: P25 = +1.00D,8 years old: P25 = +0.88D,9 years old: P25 = +0.63D.\n4. After bilateral ciliary muscle paralysis, the astigmatism detected by computerized refraction is ≤1.00D.\n5. Anisometropia ≤1.5D.\n6. No other organic lesions affecting visual acuity in both eyes.\n7. Unaided visual acuity ≥0.8.\n8. Ocular intraocular pressure (IOP) ≤21 mmHg.\n\nExclusion criteria:\n\n1. Subjects who may have ocular diseases affecting vision or refractive errors (such as lens damage diseases like cataract, glaucoma, macular degeneration, corneal lesions, uveitis, retinal detachment, severe vitreous opacity, etc.).\n2. Systemic diseases: Immune system disorders, central nervous system diseases, Down syndrome, asthma, severe cardiopulmonary dysfunction, and a history of severe hepatic or renal dysfunction.\n3. Bilateral or unilateral ocular involvement with dominant strabismus or any other pathological ocular changes or acute inflammatory eye diseases.\n4. Patients who have undergone myopia control treatments, including pharmacological therapy (e.g., atropine or piperazine), orthokeratology, multifocal soft lenses, multifocal hard lenses, functional eyeglass frames, or red light therapy.\n5. Exclude patients who have used drugs affecting efficacy evaluation (e.g., anticholinergic agents: atropine, piperazine; cholinergic agents: pilocarpine) for systemic or local use within the preceding 3 months.\n6. Patients with hypersensitivity to atropine, cipretosil, or other drugs used in this study.\n7. Exclude participants who have participated in other drug clinical trials within the past 3 months.\n8. Other circumstances deemed unsuitable by the investigator.\n9. Individuals with chronic mental disorders or psychiatric abnormalities.\n10. Those with an adjustment range below 8D.",true,"9 Years",{"count":105,"type":21},233,[107,108],"PHASE1","PHASE2","A prospective multicenter study design was adopted. Children aged 6-9 years with premyopia who met the criteria were screened and administered after completion of baseline assessment. Phase I: 0-24 weeks (0-6M). 0.01% atropine eye drops, once daily, at point in both eyes. Phase II: 24-48 weeks (6-12M). According to the rate of myopia progression at 0-24 weeks (6M), the atropine concentration was increased in steps; once daily, at point in both eyes. Group A: ( SE ≤ 0.25D), continued to maintain 0.01% atropine. Group B: (0.25D \\\u003C SE ≤ 0.375D), converted to 0.02% atropine. Group C: ( SE \\> 0.375D), converted to 0.04% atropine. Followed up 5 times (0, 3, 6, 9, 12 months), collected refractive, ocular axis, intraocular pressure and other data, and recorded adverse events and cost information synchronously. Statistical analysis was carried out by covariance analysis and multivariate model, and pharmacoeconomic evaluation and drug proportion analysis were carried out.",[111],"Pre-myopia","2026-02-26",{"date":114,"type":36},"2026-03-04",{"date":116,"type":21},"2026-03-30",{"date":118,"type":21},"2027-06-30",{"name":42,"class":43},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},"100495230","microinvasive-pars-plana-vitrectomy-combined-ilm-peeling-versus-anti-vegf-intravitreal-injection-for-treatment-nave-diabetic-macular-edema-100495230","NCT05728476","Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema","Inclusion Criteria:\n\n* ≥18 years of age\n* Patients and their families fully understand the research and sign the informed consent form\n* Diagnosed with type 1 or 2 diabetes mellitus\n* Hemoglobin A1c (HbA1c) of less than 10% within 3 months\n* Clear media for adequate OCT and optical coherence tomography angiography (OCTA) images\n* Treatment-naïve DME diagnosed clinically\n* Central subfield thickness (CST) of \\>300μm and intra- or subretinal fluid seen on (spectral-domain) SD-OCT\n* Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA between 24 and 73 letters on the day of randomization\n* Treatment within 12 months of DME diagnosis\n* No contraindication of vitrectomy or conbercept intravitreal injection\n\nExclusion Criteria:\n\n* Any previous DME treatment (i.e. anti-VEGF injections, intraocular corticosteroids, macular photocoagulation)\n* Macular edema caused by other disease (i.e. neovascular age-related macular degeneration, retinal vein occlusion, uveitis)\n* Any previous intraocular surgeries (cataract surgery performed at least 3 months before study entry will not be exclusionary)\n* Vision loss caused by other ocular disease (i.e. cataract, proliferative diabetic retinopathy, glaucoma, high myopia)\n* A follow-up duration of less than 12 months\n* Severe dysfunction of the heart, liver, kidney, lung and other organs",{"count":127,"type":21},102,[129],"NA","Diabetic macular edema (DME) is the main cause of vision loss in patients with diabetes. At present, anti-vascular endothelial growth factor (VEGF) intravitreal injection is the first-line therapy for DME, nevertheless, some patients do not respond well to anti-VEGF agents and often require multiple injections, which increases the psychological and economic burden of patients. Microinvasive pars plana vitrectomy (PPV) has been proven to be safe and effective for refractory DME. However, there are few studies on treatment-naïve DME. The purpose of this study is to explore whether early PPV combined with internal limiting membrane (ILM) peeling can reduce the treatment burden of DME patients, prevent vision loss, and maintain long-term stabilization of diabetic retinopathy.",[132,133,134],"Diabetic Macular Edema","Pars Plana Vitrectomy","Conbercept","RECRUITING","2024-03-05",{"date":138,"type":36},"2024-03-06",{"date":136,"type":36},{"date":141,"type":21},"2026-09-05",{"name":42,"class":43},1,""]